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abstract
PURPOSE The KRISTINE study compared neoadjuvant trastuzumab emtansine plus pertuzumab (T-DM1+P)
with docetaxel, carboplatin, trastuzumab plus P (TCH+P) for the treatment human epidermal growth factor
receptor 2–positive stage II to III breast cancer. T-DM1+P led to a lower pathologic complete response rate
(44.4% v 55.7%; P = .016), but fewer grade 3 or greater and serious adverse events (AEs). Here, we present
3-year outcomes from KRISTINE.
METHODS Patients were randomly assigned to neoadjuvant T-DM1+P or TCH+P every 3 weeks for six cycles.
Patients who received T-DM1+P continued adjuvant T-DM1+P, and patients who received TCH+P received
adjuvant trastuzumab plus pertuzumab. Secondary end points included event-free survival (EFS), overall
survival, patient-reported outcomes (measured from random assignment), and invasive disease-free survival
(IDFS; measured from surgery).
RESULTSOf patients, 444 were randomly assigned (T-DM1+P, n = 223; TCH+P, n = 221). Median follow-up was
37months. Risk of an EFS event was higher with TDM-1+P (hazard ratio [HR], 2.61 [95% CI, 1.36 to 4.98]) with
more locoregional progression events before surgery (15 [6.7%] v 0). Risk of an IDFS event after surgery was
similar between arms (HR, 1.11 [95% CI, 0.52 to 2.40]). Pathologic complete response was associated with
a reduced risk of an IDFS event (HR, 0.24 [95% CI, 0.09 to 0.60]) regardless of treatment arm. Overall, grade 3
or greater AEs (31.8% v 67.7%) were less common with T-DM1+P. During adjuvant treatment, grade 3 or
greater AEs (24.5% v 9.9%) and AEs leading to treatment discontinuation (18.4% v 3.8%) were more common
with T-DM1+P. Patient-reported outcomes favored T-DM1+P during neoadjuvant treatment and were similar to
trastuzumab plus pertuzumab during adjuvant treatment.
CONCLUSION Compared with TCH+P, T-DM1+P resulted in a higher risk of an EFS event owing to locoregional
progression events before surgery, a similar risk of an IDFS event, fewer grade 3 or greater AEs during neo-
adjuvant treatment, and more AEs leading to treatment discontinuation during adjuvant treatment.
J Clin Oncol 37:2206-2216. © 2019 by American Society of Clinical Oncology
Creative Commons Attribution Non-Commercial No Derivatives 4.0 License
INTRODUCTION
Current standard-of-care neoadjuvant regimens for the
treatment of human epidermal growth factor receptor
2 (HER2) –positive breast cancer consist of conven-
tional systemic chemotherapy plus trastuzumab-
based therapy.1 Pathologic complete response
(pCR) rates with conventional systemic chemotherapy
plus HER2 blockade have ranged from 25% to 65%,2-8
with dual HER2-targeted regimens producing in-
creased pCR rates compared with trastuzumab
alone.5,6 pCR in the breast and nodes is associated
with prolonged event-free survival (EFS) and overall
survival (OS) in patients with HER2-positive breast
cancer.9
Despite the pCR benefits of dual HER2-targeted
neoadjuvant therapy, approximately 15% of patients
will experience disease relapse or death within 3 to
5 years.10,11 In addition, these regimens are accom-
panied by toxicities that are associated with conven-
tional systemic chemotherapy, such as neutropenia
and febrile neutropenia.4,5,10 Improving outcomes and
safety among patients with HER2-positive early breast
cancer remain important goals when developing
neoadjuvant and adjuvant therapies.
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The KRISTINE study is a phase III, randomized, multicenter,
open-label study that evaluated a neoadjuvant regimen in
which conventional systemic chemotherapy is replaced with
trastuzumab emtansine (T-DM1), an antibody–drug conju-
gate that provides targeted delivery of chemotherapy
to HER2-overexpressing cells, as well as HER2 blockade,12
and is associated with a lower incidence of adverse events
(AEs) that are typically observed with conventional
chemotherapy.13,14 KRISTINE compared neoadjuvant
T-DM1 plus pertuzumab (T-DM1+P) with conventional
systemic chemotherapy—docetaxel plus carboplatin—
plus dual HER2-targeted blockade—trastuzumab and
pertuzumab—in patients with HER2-positive breast can-
cer. As reported previously, the T-DM1–based regimen led
to a statistically significantly lower pCR rate in the breast
and nodes (ypT0/is, ypN0) than the conventional systemic
chemotherapy–based regimen (44.4% v 55.7%; difference of
11.3 percentage points [95% CI, 220.5 to 22.0] P = .016);
however, fewer grade 3 or greater (13.0% v 64.4%) and
serious AEs (4.9% v 28.8%) were observed with the
T-DM1–based regimen in the neoadjuvant phase.12 Here,
we report the final results, which include 3-year efficacy,
safety, and patient-reported outcomes (PROs) from
KRISTINE.
METHODS
Study Design
Comprehensive methods were published with the primary
results.12 KRISTINE is a randomized, open-label, multi-
center, phase III study that was conducted at 68 Trans-
lational Research In Oncology centers in 10 countries and
in accordance with the International Council on Harmo-
nization Good Clinical Practice guidelines and the Decla-
ration of Helsinki. The institutional review board and/or
ethics committee at each site approved the protocol and all
patients provided written informed consent.
Patients
Eligible patients were age 18 years or older with clinical
stage cT2 to cT4 (. 2 cm)/cN0 to cN3/cM0 (. 2 cm)
disease confirmed by a central laboratory (Targos Molec-
ular Pathology, Kassel, Germany), to be HER2-positive
breast cancer (immunohistochemistry 3+ [PATHWAY
anti-HER2/neu {4B5} assay; Ventana Medical Systems,
Santa Clara, CA]), or in situ hybridization–positive, defined
as a HER2/CEP17 ratio of 2 or greater (INFORMHER2 Dual
ISH assay; Ventana Medical Systems).15 Both tests were
conducted in parallel for all patients; however, only one test
needed to be positive to establish HER2-positive status.
Procedures
Patients were randomly assigned 1:1 to neoadjuvant
treatment with T-DM1+P or docetaxel, carboplatin, tras-
tuzumab plus pertuzumab (TCH+P) under a permuted
block randomization scheme. Random assignment was
stratified by hormone receptor status (estrogen receptor
and/or progesterone receptor positive v estrogen receptor
negative and progesterone receptor negative on local as-
sessment), clinical stage at presentation (II to IIIA v IIIB to
IIIC), and geographic location (North America v Western
Europe v rest of world).
Patients who were randomly assigned to T-DM1+P re-
ceived T-DM1 (3.6 mg/kg) and P (840-mg loading dose
and 420-mg maintenance doses) during both the neo-
adjuvant and adjuvant phases of the study. Patients who
were randomly assigned to TCH+P received TC+H (8-
mg/kg loading dose and 6-mg/kg maintenance doses), and
P (840-mg loading dose and 420-mg maintenance doses)
during the neoadjuvant phase and continued trastuzumab
plus pertuzumab (H+P) only during the adjuvant phase. In
both study arms, HER2-targeted treatment was adminis-
tered every 3 weeks for a total of 18 cycles—inclusive of
neoadjuvant and adjuvant therapy—or until disease pro-
gression/recurrence, unacceptable toxicity, or withdrawal
of consent. Patients who discontinued T-DM1 before
treatment completion could switch treatment to trastuzu-
mab with continuation of pertuzumab when clinically ap-
propriate to complete 18 cycles of HER2-targeted therapy.
Patients underwent definitive breast cancer surgery be-
tween 14 days and 6 weeks after the last dose of neo-
adjuvant therapy. Within 9 weeks of surgery, patients
resumed HER2-targeted therapy to which they had been
previously randomly assigned—T-DM1+P or H+P—for 12
cycles. Additional adjuvant chemotherapy was permitted in
the T-DM1+P arm at the discretion of the treating physician
before adjuvant HER2-targeted therapy; it was recom-
mended for patients in the T-DM1+P arm with residual
tumor greater than 1 cm and/or residual nodal disease
(greater than ypN0). Adjuvant radiotherapy and endocrine
therapy were administered as clinically indicated per local
practice.
End Points
The primary efficacy end point was locally determined pCR
(ypT0/is, ypN0), as described previously.12 Protocol-
defined secondary efficacy end points included EFS, de-
fined as the time from random assignment to disease
progression, including local progression before surgery;
disease recurrence—local, regional, distant, ipsilateral
noninvasive, or contralateral (invasive or noninvasive)—or
death from any cause; invasive disease-free survival (IDFS),
defined as the time from surgery to the first documented
occurrence of an event defined as ipsilateral invasive local
recurrence, ipsilateral locoregional invasive recurrence,
distant recurrence, contralateral invasive breast cancer, or
death from any cause; and OS. The definition of IDFS was
consistent with the standardized definitions for efficacy end
points (STEEP) criteria, with the exception that nonbreast
second primary invasive cancer was not included.16
Protocol-defined PRO objectives included assessment of
global health status/health-related quality of life, patient
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functioning, disease- and treatment-related symptoms as
measured by the European Organization for Research and
Treatment of Cancer (EORTC) Quality-of-Life Questionnaire
(QLQ)-C30 and breast cancer module (QLQ-BR23). Se-
verity of AEs were categorized on the basis of on National
Cancer Institute Common Terminology Criteria for Adverse
Events, version 4.0.
Statistical Analysis
Secondary efficacy end points, including EFS and OS, were
analyzed in the intention-to-treat population. Analysis of
IDFS was completed only for patients who underwent
surgery as recorded in the database—that is, the IDFS-
evaluable population—consistent with the IDFS definition.
Analysis of secondary end points was not event driven, but,
rather, preplanned to occur approximately 36 months after
random assignment. The study was not powered to detect
statistically significant differences between treatment arms
in EFS, IDFS, or OS; therefore, these end points were
analyzed descriptively without formal a allocation and
P values are not presented. We used the stratified Cox
proportional hazards regression model to estimate hazard
ratios (HRs) and CIs, using TCH+P as the reference arm.
Analyses were stratified for hormone receptor status and
clinical stage at presentation. Kaplan-Meier estimates for 3-
year event-free rates were reported for EFS, IDFS, and OS,
along with corresponding 95% CIs that were calculated
using the linear transformation. For the primary analysis of
EFS and IDFS, patients were not censored for the initiation
of nonprotocol anticancer therapy. Sensitivity analyses of
EFS and IDFS were performed when patients were cen-
sored for the initiation of nonprotocol anticancer therapy.
We performed additional post hoc analysis of IDFS
according to pCR status and hormone receptor status.
Analysis of PRO end points was completed in patients who
had both baseline and one or more postbaseline assess-
ment. In accordance with the scoring manual, summary
statistics of linear transformed scores were computed for
the QLQ-C30 and QLQ-BR23 scales for each assessment
timepoint. If more than 50% of the constituent items on the
QLQ-C30 and QLQ-BR23 scales were completed, a pro-
rated score was computed.17 For scales with less than 50%
of the items completed, the scale was considered missing.
Mean change of the linear transformed scores from
baseline—and SEs—were computed for each assessment
timepoint.
RESULTS
From June 2014 to June 2015, 444 patients were randomly
assigned (T-DM1+P, n = 223; TCH+P, n = 221; Fig 1 and
Appendix Table A1, online only), and all but two patients in
the TCH+P arm received one or more dose of study
medication.12 Baseline characteristics were balanced be-
tween arms (Appendix Table A2, online only). Hormone
receptor–positive disease was present in 62.2% of patients,
and 83.1% had clinical stage IIA to IIIA disease, 66.4%
were white, and 25.2% were Asian. Median duration of
follow-up was 36.8 months (95% CI, 36.5 to 37.2 months)
in the T-DM1+P arm and 36.9 months (95% CI, 36.5 to
37.4 months) in the TCH+P arm.
Efficacy
Risk of an EFS event was greater in the T-DM1+P arm than
in the TCH+P arm (stratified HR, 2.61 [95% CI, 1.36 to
4.98]; Fig 2) as a result of more locoregional progression
events in the T-DM1+P arm before surgery (15 [6.7%] v 0)
and noninvasive recurrence events after surgery (3 [1.3%]
v 0; Table 1). Three-year EFS event-free rates were 85.3%
(95% CI, 80.5% to 90.1%) with T-DM1+P and 94.2%
(95% CI, 91.0% to 97.4%) with TCH+P.
Risk of an IDFS event in the IDFS-evaluable population was
similar between study arms (stratified HR, 1.11 [95% CI,
0.52 to 2.40]; Table 1 and Fig 3A). Three-year IDFS event-
free rates were 93.0% (95% CI, 89.4% to 96.7%) with
T-DM1+P and 92.0% (95% CI, 86.7% to 97.3%) with
TCH+P. OS was also similar between arms—six deaths in
the T-DM1+P arm and five in the TCH+P arm (Table 1)
—but the number of deaths was too low to drawmeaningful
conclusions.
IDFS was analyzed according to pCR status in the IDFS-
evaluable population (Table 2 and Figs 2C and 2D). Among
all patients who underwent surgery (n = 418), pCR was
associated with a reduced risk of an IDFS event regardless of
treatment arm or hormone receptor status (stratified HR,
0.24 [95% CI, 0.09 to 0.60]). In patients with a pCR, risk of
an IDFS event was similar between treatment arms (stratified
HR, 0.99 [95% CI, 0.20 to 4.96]). The 3-year IDFS event-
free rate was similarly high in the T-DM1+P arm (96.7%
[95% CI, 93.0% to 100.0%]) and TCH+P arm (97.5% [95%
CI, 94.7% to 100.0%]). In patients with residual disease—
regardless of whether they received optional adjuvant che-
motherapy—risk of an IDFS event was also similar between
treatment arms (stratified HR, 0.94 [95% CI, 0.38 to 2.33]).
The 3-year IDFS event-free rate was 89.4% (95% CI, 83.1%
to 95.6%) in the T-DM1+P arm and 84.2% (95% CI, 72.5%
to 96.0%) in the TCH+P arm. A similar risk of an IDFS event
in both arms was also observed in subgroups defined by
hormone receptor status (Appendix Table A3, online only).
Sensitivity analyses for EFS and IDFS were conducted that
censored patients at the time that they initiated nonprotocol
anticancer therapy. Results of these sensitivity analyses were
completely aligned with the results of the primary analyses for
both EFS and IDFS (Appendix Table A4, online only).
Adjuvant chemotherapy, endocrine therapy, and/or radi-
ation therapy—in addition to T-DM1+P or H+P—was re-
ceived on study by 159 (77.9%) of 204 patients in the
T-DM1+P arm and 178 (83.2%) of 214 patients in the
TCH+P arm (Appendix Table A5, online only). Chemo-
therapy was administered to 50 patients (24.5%) in the
T-DM1+P arm (41 [33.1%] of 124 patients with residual
2208 © 2019 by American Society of Clinical Oncology Volume 37, Issue 25
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disease and nine [9.1%] of 99 patients with pCR) and to no
patients in the TCH+P arm.
Safety
In the T-DM1+P arm, median treatment durations were
12.6 months (range, 0.7 to 18.6 months) for T-DM1 and
12.9 months (range, 0.7 to 18.6 months) for P (Appendix
Table A6, online only). In the TCH+P arm, median treatment
durations were 3.5months (range, 0 to 4.8months) for T and
C, and 12.9 months (range, 0 to 16.6 months) for H and P.
Dose reductions of T-DM1 occurred in 19.3% of patients.
Of 196 patients who received adjuvant T-DM1+P, 17 (8.7%)
switched to H+P as a result of AEs.
During the overall study period, including both neoadjuvant
and adjuvant phases, there was a lower incidence of serious
(13.5% v 32.4%) and grade 3 or greater (31.8% v 67.6%)
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FIG 1. Patient disposition.
EFS, event-free survival;
IDFS, invasive disease-free
survival; TCH+P, docetaxel,
carboplatin, and trastuzu-
mab plus pertuzumab;
T-DM1+P, trastuzumab
emtansine plus pertuzumab.
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FIG 2. (A) Kaplan-Meier
analysis of event-free sur-
vival in the intention-to-
treat population. Event-free
survival was defined as the
time from random assign-
ment to disease progression
(including local progression
before surgery), disease
recurrence (local, regional,
distant, ipsilateral non-
invasive, or contralateral
[invasive or noninvasive]),
or death from any cause.
(B-D) Kaplan-Meier anal-
ysis of invasive disease-
free survival in the in-
tention-to-treat population
who underwent surgery
according to (B) treatment
arm, (C) pathologic com-
plete response (pCR) sta-
tus, and (D) treatment arm
and pCR status. Invasive
disease-free survival was
defined as the time from
surgery to the first docu-
mented occurrence of ip-
silateral invasive local
recurrence, ipsilateral
locoregional invasive recur-
rence, distant recurrence,
contralateral invasive breast
cancer, or death from any
cause. TCH+P, docetaxel,
carboplatin, and trastuzu-
mab plus pertuzumab;
T-DM1+P, trastuzumab
emtansine plus pertuzumab.
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AEs in the T-DM1+P arm compared with the TCH+P arm,
driven by the better safety profile of T-DM1+P comparedwith
TCH+P in the neoadjuvant phase (Table 3). Throughout the
study, the four most commonly occurring grade 3 or greater
AEs in the T-DM1+P arm were anemia (5.8%), neutropenia
(3.6%), peripheral neuropathy (3.1%), and decreased
platelet count (2.2%). The four most commonly occurring
grade 3 or greater AEs in the TCH+P arm were neutropenia
(25.1%), diarrhea (15.5%), febrile neutropenia (15.1%),
and anemia (11%). Throughout the study, serious AEs that
occurred in 1% or more of the T-DM1+P arm were febrile
neutropenia (1.3%), anemia (1.3%), and wound infection
(1.3%). In the TCH+P arm, these were febrile neutropenia
(11.9%), diarrhea (4.1%), neutropenia (3.2%), vomiting
(1.8%), colitis (1.4%), and decreased neutrophil count
(1.4%). Symptomatic New York Health Association Class III
or IV heart failure was reported in no patients receiving
T-DM1+P and in three patients (1.4%) receiving TCH+P.
During adjuvant treatment, grade 3 or greater AEs, serious
AEs, and AEs leading to the discontinuation of any com-
ponent of treatment were more common in patients who
received T-DM1+P (25.5% [50 of 196 patients in the safety
population] of whom also received adjuvant conventional
systemic chemotherapy) versus those who received H+P
(Table 3). Grade 3 or greater AEs occurred in 48 patients
(24.5%) and 21 patients (9.9%), respectively. Serious AEs
occurred in 13 patients (6.6%) and 10 patients (4.7%),
respectively. AEs that led to the discontinuation of any
component of treatment occurred in 36 patients (18.4%)
and eight patients (3.8%), respectively. Those occurring in
at least two patients are shown in Appendix Table A7
TABLE 1. Time-to-Event Efficacy End Points
End Point T-DM1+P (n = 223) TCH+P (n = 221)
EFS
Patients included in analysis, No. 223 221
Event, No. (%) 31 (13.9) 13 (5.9)
Locoregional progression before surgery 15 (6.7) 0
Invasive disease recurrence after surgery 11 (4.9) 11 (5.0)
Noninvasive recurrence (DCIS) after surgery 3 (1.3) 0
Death without prior EFS event 2 (0.9) 2 (0.9)
Stratified HR for T-DM1+P v TCH+P (95% CI)* 2.61 (1.36 to 4.98)
3-Year EFS, % (95% CI) 85.3 (80.5 to 90.1) 94.2 (91.0 to 97.4)
IDFS
Patients included in analysis, No. 204 214
Event, No. (%)† 13 (6.4) 13 (6.1)
Distant recurrence, CNS 4 (2.0) 4 (1.9)
Distant recurrence, non-CNS 5 (2.5) 5 (2.3)
Locoregional recurrence 2 (1.0) 2 (0.9)
Contralateral breast cancer 0 0
Death without prior IDFS event 2 (1.0) 2 (0.9)
Stratified HR for T-DM1+P v TCH+P (95% CI)* 1.11 (0.52 to 2.40)
3-Year IDFS event-free survival, % (95% CI) 93.0 (89.4 to 96.7) 92.0 (86.7 to 97.3)
OS
Patients included in analysis, No. 223 221
Deaths, No. (%) 6 (2.7) 5 (2.3)
Stratified HR for T-DM1+P v TCH+P (95% CI)* 1.21 (0.37 to 3.96)
3-Year OS event-free survival, % (95% CI) 97.0 (94.6 to 99.4) 97.6 (95.5 to 99.7)
Abbreviations: DCIS, ductal carcinoma in situ; EFS, event-free survival; HR, hazard ratio; IDFS, invasive disease-free survival; OS, overall
survival; TCH+P, docetaxel, carboplatin, and trastuzumab plus pertuzumab; T-DM1+P, trastuzumab emtansine plus pertuzumab.
*Stratified for hormone receptor status (estrogen receptor positive and/or progesterone receptor positive versus estrogen receptor negative and
progesterone receptor negative) and clinical stage at presentation (II-IIIA v IIIB-IIIC).
†Patients who experience more than one IDFS event are reported in the category associated with their earliest IDFS event. If more than one
event is reported on the same date, patients are reported in the category according to the following hierarchy: 1) distant recurrence, CNS; 2)
distant recurrence, non-CNS; 3) locoregional recurrence; 4) contralateral breast cancer; and 5) death without prior event.
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(online only). Among the 146 patients in the T-DM1+P arm
who received no adjuvant chemotherapy, serious AEs
occurred in six patients (4.1%), grade 3 or greater AEs
occurred in 25 patients (17.1%), and AEs leading to the
discontinuation of any component of treatment occurred in
22 patients (15.1%). During the adjuvant phase, one pa-
tient in the T-DM1+P arm died of an ileus AE after starting
adjuvant chemotherapy that was deemed related to ad-
juvant chemotherapy.
PROs
Across visits, more than 80% of patients completed one or
more question on the EORTC QLQ-C30 and QLQ-BR23.
The response rate was similar between treatment arms. An
optional assessment was administered to patients who
received adjuvant chemotherapy in the T-DM1+P arm. Of
50 patients, 44 were eligible to complete the optional cycle
4 assessment, which occurred before cycle 4 of chemo-
therapy and 28 (63.6%) completed one or more question.
Baseline scores were well balanced between study arms
(Appendix Table A8, online only). Patients who received
T-DM1+P reported fewer impairments on the QLQ-C30 and
QLQ-BR23 during neoadjuvant treatment than did patients
who received TCH+P, including on assessments of global
health status, physical functioning, cognitive functioning,
and diarrhea (Fig 3). Similar scores were observed in each
treatment arm on the QLQ-C30 and QLQ-BR23 scales
during adjuvant treatment, and impairments generally re-
solved to baseline levels during follow-up; however, slight
impairment in cognitive functioning remained at the final
follow-up visit in both treatment arms. For the group of
T-DM1+P patients who received adjuvant chemotherapy,
impairments were observed in global health status, physical
functioning, and cognitive functioning, as well as an in-
crease in diarrhea at the optional assessment.
DISCUSSION
This phase III randomized study demonstrated that
replacing systemic chemotherapy with T-DM1 in an HER2-
targeted neoadjuvant regimen led to a greater risk of an EFS
event (HR, 2.61 [95%CI, 1.36 to 4.98]), but a similar risk of
an IDFS event (HR, 1.11 [95% CI, 0.52 to 2.40]) compared
with TCH+P in patients with operable, HER2-positive stage
II to III breast cancer. The higher risk of an EFS event in the
T-DM1+P arm was driven by investigator-assessed
locoregional progression before surgery (n = 15 [6.7%])
and noninvasive recurrence postsurgery (n = 3 [1.3%]) in
the T-DM1+P arm, whereas no such events occurred in the
TCH+P arm. Tumors from the 15 patients who experienced
locoregional progression had lower HER2 expression and
higher HER2 heterogeneity relative to those from other
patients in the T-DM1 arm (Appendix Tables A9 and A10,
online only). These data suggest that patients with low and/
or heterogenous HER2 expression may require conven-
tional systemic chemotherapy combined with HER2
blockade. A relationship between the level of HER2 ex-
pression and the extent of T-DM1 benefit has also been
noted in the metastatic setting. Whereas T-DM1 therapy
was superior to conventional therapy in all patient subsets,
the benefits were greater in those with HER2 mRNA
expression greater than the median for the study
population.18,19
After surgery, analysis of the IDFS-evaluable population
showed no difference between arms in the risk of an IDFS
TABLE 2. IDFS According to pCR Status in the IDFS-Evaluable Population
Characteristic Patients With Residual Disease (n = 195) Patients With pCR (n = 223)
Event, No. (%) 20 (10.3) 6 (2.7)
IDFS event 17 (8.7) 5 (2.2)
Death without prior IDFS event 3 (1.5) 1 (0.4)
Stratified HR for pCR v residual disease (95% CI)* 0.24 (0.09 to 0.60)
3-Year IDFS event-free survival, % (95% CI) 87.4 (81.6 to 93.3) 97.2 (94.9 to 99.4)
T-DM1+P (n = 105) TCH+P (n = 90) T-DM1+P (n = 99) TCH+P (n = 124)
Event, No. (%) 10 (9.5) 10 (11.1) 3 (3.0) 3 (2.4)
IDFS event 8 (7.6) 9 (10.0) 3 (3.0)† 2 (1.6)‡
Death without prior IDFS event 2 (1.9) 1 (1.1) 0 1 (0.8)
Stratified HR for T-DM1+P v TCH+P (95% CI)* 0.94 (0.38 to 2.33) 0.99 (0.20 to 4.96)
3-Year IDFS event-free survival, % (95% CI) 89.4 (83.1 to 95.6) 84.2 (72.5 to 96.0) 96.7 (93.0 to 100) 97.5 (94.7 to 100)
Abbreviations: HR, hazard ratio; IDFS, invasive disease-free survival; pCR, pathologic complete response; TCH+P, docetaxel, carboplatin, and
trastuzumab plus pertuzumab; T-DM1+P, trastuzumab emtansine plus pertuzumab.
*Stratified for hormone receptor status (estrogen receptor positive and/or progesterone receptor positive versus estrogen receptor negative and
progesterone receptor negative) and clinical stage at presentation (II-IIIA v IIIB-IIIC). Not adjusted for treatment arm.
†Included one distant non-CNS recurrence and two distant CNS recurrences.
‡Included two distant CNS recurrences.
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event; however, 95% CI is wide for the IDFS HR (0.52 to
2.40), and the 15 patients who experienced locoregional
progression in the T-DM1+P arm before surgery were not
included in the IDFS-evaluable population; therefore, IDFS
results should be interpreted with caution. In addition,
within the T-DM1+P arm, patients who had residual dis-
ease were more likely to have received adjuvant chemo-
therapy than patients who had a pCR (33.1% v 9.1%). Lack
TABLE 3. Safety
Adverse Event
Adverse Event Summary
Overall Study Neoadjuvant Phase Adjuvant Phase
T-DM1+P
(n = 223)
TCH+P
(n = 219)
T-DM1+P
(n = 223)
TCH+P
(n = 219)
T-DM1+P
(n = 196)
TCH+P
(n = 212)
Any 214 (96.0) 219 (100) 197 (88.3) 216 (98.6) 174 (88.8) 177 (83.5)
Serious 30 (13.5) 71 (32.4) 11 (4.9) 63 (28.8) 13 (6.6) 10 (4.7)
Grade $ 3 71 (31.8) 148 (67.6) 29 (13.0) 141 (64.4) 48 (24.5) 21 (9.9)
Death as a result of any cause 6 (2.7) 5 (2.3) 0 0 1 (0.5) 0
Adverse event leading to death* 1 (0.4) 0 0 0 1 (0.5) 0
Symptomatic NYHA Class III
or IV heart failure
0 3 (1.4) — — — —
Asymptomatic confirmed decrease
in LVEF of $ 10 percentage points
from baseline to an LVEF , 50%
1 (0.4) 4 (1.8) — — — —
Adverse event leading to
treatment discontinuation
T-DM1: 45 (20.2) T: 10 (4.6) T-DM1: 7 (3.1) T: 11 (5.0) T-DM1: 36 (18.4) H: 5 (2.4)
P: 26 (11.7) C: 17 (7.8) P: 3 (1.3) C: 17 (7.8) P: 22 (11.2) P: 8 (3.8)
H: 9 (4.1) H: 3 (1.4)
P: 13 (5.9) P: 5 (2.3)
Grade ‡ 3 Adverse Events Occurring in ‡ 2% of Patients in Either Group During Any Study Phase
Adverse Event
Overall Study Neoadjuvant Phase Adjuvant Phase
T-DM1+P
(n = 223)
TCH+P
(n = 219)
T-DM1+P
(n = 223)
TCH+P
(n = 219)
T-DM1+P
(n = 196)
TCH+P
(n = 212)
Neutropenia 8 (3.6) 55 (25.1) 1 (0.4) 55 (25.1) 8 (4.1) 0
Diarrhea 4 (1.8) 34 (15.5) 2 (0.9) 33 (15.1) 2 (1.0) 2 (0.9)
Febrile neutropenia 4 (1.8) 33 (15.1) 0 33 (15.1) 4 (2.0) 0
Anemia 13 (5.8) 24 (11.0) 2 (0.9) 21 (9.6) 8 (4.1) 1 (0.5)
Neutrophil count decreased 3 (1.3) 20 (9.1) 0 20 (9.1) 3 (1.5) 0
Platelet count decreased 5 (2.2) 11 (5.0) 3 (1.3) 11 (5.0) 2 (1.0) 0
WBC count decreased 2 (0.9) 9 (4.1) 0 9 (4.1) 2 (1.0) 0
Hypokalemia 4 (1.8) 8 (3.7) 3 (1.3) 5 (2.3) 1 (0.5) 1 (0.5)
Hypertension 1 (0.4) 8 (3.7) 1 (0.4) 7 (3.2) 0 1 (0.5)
Vomiting 2 (0.9) 7 (3.2) 1 (0.4) 7 (3.2) 1 (0.5) 0
Fatigue 2 (0.9) 7 (3.2) 3 (1.3) 7 (3.2) 0 0
Asthenia 0 6 (2.7) 0 6 (2.7) 0 0
Thrombocytopenia 2 (0.9) 5 (2.3) 1 (0.4) 4 (1.8) 1 (0.5) 0
ALT increased 4 (1.8) 5 (2.3) 3 (1.3) 4 (1.8) 1 (0.5) 0
Peripheral neuropathy 7 (3.1) 1 (0.5) 1 (0.4) 1 (0.5) 6 (3.1) 0
NOTE. Data are given as No. (%).
Abbreviations: C, carboplatin; H, trastuzumab; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; P, pertuzumab; T, docetaxel;
TCH+P, docetaxel, carboplatin, and trastuzumab plus pertuzumab; T-DM1, trastuzumab emtansine; T-DM1+P, trastuzumab emtansine plus pertuzumab.
*The patient died of an ileus adverse event with onset after the patient had received two cycles of cyclophosphamide and epirubicin from day 148 to day
169. The patient died on day 177. Death was attributed to adjuvant chemotherapy.
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FIG 3. Patient-reported outcomes during the overall study period for patients in the intention-to-treat population. Graphs depict mean change from
baseline in European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire2C30 for domains of (A) global health status,
(B) physical functioning, (C) cognitive functioning, and (D) diarrhea. Baseline is defined as neoadjuvant cycle 1, day 1. TCH+P, docetaxel, car-
boplatin, and trastuzumab plus pertuzumab; T-DM1+P, trastuzumab emtansine plus pertuzumab.
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of randomization to adjuvant chemotherapy and the small
number of patients who received it preclude meaningful
analyses of this subgroup. Consistent with other data,9 pCR
conferred a favorable long-term outcome compared with
no pCR (stratified HR, 0.24 [95% CI, 0.09 to 0.60]) re-
gardless of treatment arm, with 3-year IDFS event-free rates
of 96.7% in the T-DM1+P arm and 97.5% in the TCH+P
arm. A relationship between pCR and a favorable 3-year
outcome was also apparent regardless of hormone receptor
status.
During the overall study period, T-DM1+P was associated
with fewer grade 3 or greater and serious AEs than TCH+P
followed by adjuvant H+P, which was driven by a better
safety profile in the T-DM1+P arm compared with the
TCH+P arm during the neoadjuvant treatment phase.
However, during the adjuvant phase, compared with H+P,
T-DM1+P was associated with a greater incidence of grade
3 or greater AEs, serious AEs, and AEs that led to treatment
discontinuation. The increased incidence of these AEs in
the T-DM1+P arm seem to be driven, at least in part,
by adjuvant chemotherapy. Serious AEs occurred in 14.0%
(seven of 50) of patients who received adjuvant chemo-
therapy versus in 4.1% (six of 146) of patients who did not.
Grade 3 or greater AES occurred in 46.0% (23 of 50) of
patients who received adjuvant chemotherapy versus in
17.1% (25 of 146) of patients who did not, and AEs leading
to treatment discontinuation occurred in 28.0% (14 of 50)
of patients who received adjuvant chemotherapy versus in
15.1% (22 of 146) of patients who did not.
Treatment with T-DM1+P resulted in less functional im-
pairment and less impact from symptoms compared with
TCH+P during the neoadjuvant phase of treatment, as
assessed by EORTC QLQ-C30 (Fig 3) and QLQ-BR23 (data
not shown). Although impairments in cognitive functioning
and certain symptoms remained through the adjuvant
phase and follow-up in both arms, a large negative impact
on physical or role functioning or global health status was
not observed.
The role of T-DM1 in early HER2-positive breast cancer is
evolving, with two trials evaluating this agent in the adjuvant
setting. The KATHERINE trial demonstrates that patients
who had residual disease after neoadjuvant systemic
chemotherapy plus single or dual HER2-directed therapy
had a lower risk of invasive breast cancer recurrence or
death with adjuvant T-DM1 compared with adjuvant tras-
tuzumab (HR, 0.50 [95% CI, 0.39 to 0.64]; P , .001).20
The ongoing KAITLIN trial (ClinicalTrials.gov identifier:
NCT01966471) will compare T-DM1+P with taxane plus
P+H after anthracyclines as adjuvant therapy for patients
who have not received prior neoadjuvant therapy and will
thus provide additional information on outcomes with ad-
juvant T-DM1+P.
Strengths of the current study were its rigorous randomized
controlled design and its use of dual HER2-targeted
therapy as the control in both the neoadjuvant and adju-
vant phases. Limitations were that the end points of EFS,
IDFS, and OS were secondary and the study was not
powered to detect differences in these end points. In ad-
dition, the 15 patients who experienced locoregional pro-
gression in the T-DM1+P armwere not included in the IDFS
analysis because they did not have surgery recorded in the
case report form and their disease recurrence status was
not available; however, some of these patients were still in
the OS follow-up.
Three-year results from KRISTINE demonstrate that neo-
adjuvant and adjuvant T-DM1+P was associated with
a higher risk of an EFS event, a similar risk of an IDFS event,
and less quality-of-life impairment in the neoadjuvant
phase compared with neoadjuvant TCH+P followed by
adjuvant H+P. Furthermore, relative to TCH+P followed by
adjuvant H+P, the conventional systemic chemo-
therapy–sparing regimen of T-DM1+P was associated with
fewer serious AEs, grade 3 or greater AEs, and more AEs
leading to treatment discontinuation. Overall, the observed
worse EFS and similar IDFS associated with T-DM1+P
might suggest the importance of selecting patients for
a conventional chemotherapy–sparing neoadjuvant regi-
men. Data from KAITLIN will further define the clinical utility
of adjuvant T-DM1+P in patients with HER2-positive early
breast cancer.
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APPENDIX
TABLE A1. Treatment Disposition During Overall Study
Variable
T-DM1+P (n = 223) TCH+P (n = 221)
T-DM1 P T C H P
Discontinuation by component, No. (%) 74 (33.2) 59 (26.5) 13 (5.9) 19 (8.6) 18 (8.1) 22 (10.0)
Reason, No. (%)
Death 1 (0.4) 1 (0.4) 0 0 0 0
Adverse event 43 (19.3) 24 (10.8) 11 (5.0) 17 (7.7) 9 (4.1) 13 (5.9)
Locoregional progression 15 (6.7) 15 (6.7) 0 0 0 0
Invasive breast cancer relapse 1 (0.4) 2 (0.9) — — 1 (0.5) 1 (0.5)
New nonbreast primary malignancy 2 (0.9) 2 (0.9) 0 0 0 0
Patient decision 5 (2.2) 5 (2.2) 1 (0.5) 1 (0.5) 3 (1.4) 3 (1.4)
Physician decision 3 (1.3) 3 (1.3) 0 0 1 (0.5) 1 (0.5)
Noncompliance 1 (0.4) 1 (0.4) 0 0 1 (0.5) 1 (0.5)
Lost to follow-up 1 (0.4) 1 (0.4) 0 0 0 0
Other 2 (0.9) 5 (2.2) 1 (0.5) 1 (0.5) 3 (1.4) 3 (1.4)
Abbreviations: C, carboplatin; H, trastuzumab; P, pertuzumab; T, docetaxel; TCH+P, docetaxel, carboplatin, and trastuzumab plus
pertuzumab; T-DM1, trastuzumab emtansine; T-DM1+P, trastuzumab emtansine plus pertuzumab.
TABLE A2. Baseline Characteristics
Characteristic T-DM1+P (n = 223) TCH+P (n = 221)
Median age, years (range) 50.0 (23-79) 49.0 (22-79)
Local ER/PR status, No. (%)
ER positive and/or PR positive 139 (62.3) 137 (62.0)
ER and PR negative 84 (37.7) 84 (38.0)
Clinical stage at initial diagnosis, No. (%)
IIA-IIIA 186 (83.4) 183 (82.8)
IIIB-IIIC 37 (16.6) 38 (17.2)
Race, No. (%)
White 148 (66.4) 147 (66.5)
Black 5 (2.2) 6 (2.7)
Asian 60 (26.9) 52 (23.5)
Other* 10 (4.5) 16 (7.2)
Median time from breast cancer diagnosis, weeks (range) 5.0 (2.3-14.0) 5.3 (1.4-129.3)
Abbreviations: ER, estrogen receptor; PR, progesterone receptor; TCH+P, docetaxel, carboplatin, and trastuzumab plus pertuzumab;
T-DM1+P, trastuzumab emtansine plus pertuzumab.
*Includes American Indian/Alaska Native, Native Hawaiian or other Pacific Islander, multiple, and not available.
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TABLE A3. IDFS According to Tumor Hormone Receptor Status in the IDFS-Evaluable Population
Variable
ER and PR Negative ER and/or PR Positive
T-DM1+P (n = 84) TCH+P (n = 84) T-DM1+P (n = 139) TCH+P (n = 137)
Patients included in analysis, No. 77 80 127 134
Event, No. (%) 4 (5.2) 6 (7.5) 9 (7.1) 7 (5.2)
IDFS event 4 (5.2) 6 (7.5) 7 (5.5) 5 (3.7)
Death without prior IDFS event 0 0 2 (1.6) 2 (1.5
Stratified HR for T-DM1+P v TCH+P (95% CI)* 0.73 (0.21 to 2.60) 1.44 (0.54 to 3.88)
3-Year IDFS event-free survival, % (95% CI) 94.4 (89.1 to 99.7) 92.5 (86.7 to 98,3) 92.2 (87.3 to 97.1) 91.7 (84.1 to 99.4)
Abbreviations: ER, estrogen receptor; HR, hazard ratio; IDFS, invasive disease-free survival; PR, progesterone receptor; TCH+P, docetaxel,
carboplatin, and trastuzumab plus pertuzumab; T-DM1+P, trastuzumab emtansine plus pertuzumab.
*Stratified for clinical stage at presentation (II-IIIA v IIIB-IIIC).
TABLE A4. Sensitivity Analysis for EFS and IDFS Censoring at Start of Nonprotocol Anticancer Therapy
Variable T-DM1+P TCH+P
EFS
Patients included in analysis, No. 223 221
Event, No. (%) 30 (13.5) 12 (5.4)
EFS event, No. 28 11
Death without prior EFS event, No. 2 1
Stratified HR for T-DM1+P v TCH+P (95% CI)* 2.74 (1.40 to 5.35)
3-Year IDFS event-free survival, % (95% CI) 85.6 (80.8 to 90.4) 94.6 (91.5 to 97.7)
IDFS
Patients included in analysis, No. 204 214
Event, No. (%)† 12 (5.9) 12 (5.6)
Distant recurrence, CNS, No. 4 4
Distant recurrence, non-CNS, No. 5 5
Locoregional occurrence, No. 1 2
Contralateral breast cancer, No. 0 0
Death without prior IDFS event, No. 2 1
Stratified HR for T-DM1+P v TCH+P (95% CI)* 1.12 (0.50 to 2.50)
3-Year IDFS event-free survival, % (95% CI) 93.4 (89.9 to 97.0) 92.4 (87.2 to 97.6)
Abbreviations: EFS, event-free survival; HR, hazard ratio; IDFS, invasive disease-free survival; PR, progesterone receptor; TCH+P, docetaxel,
carboplatin, and trastuzumab plus pertuzumab; T-DM1+P, trastuzumab emtansine plus pertuzumab.
*Stratified for hormone receptor status (estrogen receptor positive and/or progesterone receptor positive v estrogen receptor negative and
progesterone receptor negative) and clinical stage at presentation (II-IIIA v IIIB-IIIC).
†Patients who experience more than one IDFS event are reported in the category associated with their earliest IDFS event. If more than one
event is reported on the same date, patients are reported in the category according to the following hierarchy: 1) distant recurrence, CNS; 2)
distant recurrence, non-CNS; 3) locoregional recurrence; 4) contralateral breast cancer; and 5) death without prior event.
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TABLE A5. Additional Adjuvant Treatments in the IDFS-Evaluable Population
Treatment T-DM1+P (n = 204) TCH+P (n = 214)
At least one treatment 159 (77.9) 178 (83.2)
Radiotherapy 119 (58.3) 142 (66.4)
Breast only 70 (34.3) 83 (38.8)
Breast plus lymph nodes 47 (23.0) 57 (26.6)
Lymph nodes only 2 (1.0) 2 (0.9)
Endocrine therapy 93 (45.6) 119 (55.6)
Chemotherapy* 50 (24.5)† 0
Systemic nonprotocol antitumor therapy 1 (0.5) 1 (0.5)
NOTE. Data are presented as No. (%).
Abbreviations: IDFS, invasive disease-free survival; TCH+P, docetaxel, carboplatin, and trastuzumab plus pertuzumab; T-DM1+P,
trastuzumab emtansine plus pertuzumab.
*Data on chemotherapy regimens were not collected.
†(n = 41) with residual disease; (n = 9) with pathologic complete response.
TABLE A6. Treatment Exposure During Overall Study (safety population)
Variable
T-DM1+P* (n = 223) TCH+P (n = 219)
T-DM1 (n = 223) P (n = 223) T (n = 219) C (n = 219) H (n = 219) P (n = 219)
Median treatment duration, months (range) 12.6 (0.7-8.6) 12.9 (0.7-18.6) 3.5 (0-4.8) 3.5 (0-4.8) 12.9 (0-16.6) 12.9 (0-16.6)
Median No. of cycles (range) 18.0 (2-18) 18.0 (2-18) 6.0 (1-6) 6.0 (1-6) 18.0 (1-18) 18.0 (1-18)
Any level of dose reduction, No. (%) 43 (19.3) 0 51 (23.3) 58 (26.5) 0 0
First-level dose reduction,† No. (%) 28 (12.6) 0 45 (20.5) 57 (26.0) 0 0
Second-level dose reduction,‡ No. (%) 15 (6.7) 0 6 (2.7) 1 (0.5) 0 0
Abbreviations: C, carboplatin; H, trastuzumab; P, pertuzumab; T, docetaxel; TCH+P, docetaxel, carboplatin, and trastuzumab plus
pertuzumab; T-DM1+P, trastuzumab emtansine plus pertuzumab.
*Six patients received H during recommended adjuvant cytotoxic therapy; 17 patients received H as replacement for T-DM1 during the
adjuvant phase.
†T, 60 mg/m2; C, area under the concentration time curve 5; T-DM1, 3 mg/kg.
‡T, 50 mg/m2, C, area under the concentration time curve 4; T-DM1, 2.4 mg/kg.
TABLE A7. Adverse Events Leading to Treatment Discontinuation in at
Least Two Patients in the Adjuvant Phase
Adverse Event T-DM1+P (n = 196) H+P (n = 212)
Blood bilirubin increased 9 (4.6) 0
Peripheral neuropathy 6 (3.1) 0
Thrombocytopenia 5 (2.6) 0
Anemia 3 (1.5) 1 (0.5)
Platelet count decreased 3 (1.5) 0
Radiation pneumonitis 3 (1.5) 0
Ejection fraction decreased 2 (1.0) 0
Left ventricular dysfunction 0 2 (0.9)
NOTE. Data are presented as No. (%).
Abbreviations: H+P, trastuzumab plus pertuzumab; T-DM1+P,
trastuzumab emtansine plus pertuzumab.
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TABLE A8. Baseline Scores (ie, before cycle 1 neoadjuvant treatment) on the
European Organization for Research and Treatment of Cancer QLQ-C30 and
QLQ-BR23 by Study Arm
PRO Item T-DM1+P (n = 223) TCH+P (n = 221)
QLQ-C30 (scale range, 1-100)
Global health status 76.6 (16.9) 74.2 (18.6)
Physical functioning 93.7 (9.6) 91.7 (12.0)
Cognitive functioning 90.3 (15.4) 89.6 (15.6)
Emotional functioning 72.5 (21.4) 72.5 (20.8)
Role functioning 89.9 (16.3) 89.9 (20.9)
Social functioning 88.3 (17.2) 84.8 (22.4)
Diarrhea 4.2 (13.8) 5.8 (14.7)
Appetite loss 10.5 (20.7) 12.2 (20.4)
Constipation 7.7 (15.9) 8.5 (19.2)
Dyspnea 6.9 (16.4) 8.3 (16.3)
Fatigue 19.9 (17.4) 20.4 (20.9)
Financial difficulties 15.4 (24.5) 13.4 (22.9)
Insomnia 25.5 (26.3) 29.8 (25.9)
Nausea/vomiting 1.9 (6.5) 2.3 (8.0)
Pain 15.3 (17.2) 15.1 (21.2)
QLQ-BR23 (scale range, 1-100)
Systemic therapy adverse effects 8.8 (10.0) 10.1 (11.2)
Any hair loss 1.5 (6.9) 3.2 (10.4)
Upset by hair loss 28.6 (35.6) 33.3 (32.2)
Neuropathy 4.1 (11.9) 4.7 (13.9)
Skin problems 9.6 (17.4) 9.0 (15.8)
Body image 90.4 (14.8) 89.5 (16.1)
Sexual functioning 80.3 (23.3) 77.9 (23.5)
Sexual enjoyment 46.1 (26.1) 45.0 (25.2)
Future perspective 52.8 (28.8) 50.7 (30.0)
NOTE. Data are presented as mean (standard deviation).
Abbreviations: PRO, patient-reported outcome; QLQ-BR23, Quality-of-Life
Questionnaire–Breast Cancer Module; QLQ-C30, Quality-of-Life
Questionnaire–C30; TCH+P, docetaxel, carboplatin, and trastuzumab plus
pertuzumab; T-DM1+P, trastuzumab emtansine plus pertuzumab.
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TABLE A9. HER2 Expression in T-DM1+P Arm by Disease Progression Status Before Surgery
Variable
T-DM1+P (n = 223)
Patients With Locoregional
Disease Progression (n = 15)
Patients Without Locoregional Disease
Progression (n = 208)
Estrogen receptor and/or progesterone receptor positive, No. (%) 10 (66.7) 129 (62.0)
Median HER2 mRNA (range) 1.30 (0.4-5.2) 6.36 (0.3-86.8)
HER2 mRNA expression below the overall median, n/N (%) 14/14 (100) 96/204 (47.1)
HER2 copy number, No. (%)
, 4.0 1 (6.7) 1 (0.5)
4.0-5.9 3 (20.0) 8 (3.8)
$ 6.0 11 (73.3) 189 (90.9)
HER2 gene ratio, No. (%)
, 2.0 1 (6.7) 2 (1.0)
2.0-3.9 10 (66.7) 42 (20.2)
$ 4.0 4 (26.7) 154 (74.0)
HER2 by IHC, No. (%)
IHC 2+ 10 (66.7) 18 (8.7)
IHC 3+ 5 (33.3) 190 (91.3)
HER2 2+/3+ heterogeneity*, No. (%)
Focal (, 30%) 7 (46.7) 9 (4.3)
Heterogeneous (30-79%) 5 (33.3) 22 (10.6)
Homogeneous ($ 80%) 3 (20.0) 177 (85.1)
Abbreviations: HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; T-DM1+P, trastuzumab emtansine plus pertuzumab.
*HER2 heterogeneity categories were based on the percentage of cells that were stained positive for HER2, which was defined as the sum of cells with
complete membrane staining with 2+ or 3+ intensity. Positive staining for , 30% of cells was categorized as HER2 focal; staining of $ 30% and # 79% of
cells was categorized as HER2 heterogeneous; and staining of $ 80% of cells was categorized as HER2 homogeneous.
TABLE A10. Baseline ER and HER2 Status of Patients With Locoregional Progression in the T-DM1+P Arm
Patient No. ER/PR Status HER2 mRNA HER2 IHC HER2 ISH HER2 Gene Ratio HER2 Copy No. HER2 2+/3+ Heterogeneity
1 Positive 0.5 2+ Positive 2.5 6.1 Focal
2 Negative 0.4 2+ Positive 4.8 10.3 Heterogeneous
3 Negative 1.1 2+ Positive 2.6 4.6 Focal
4 Negative 0.7 2+ Positive 2.6 3.7 Focal
5 Positive 5.2 3+ Positive 4.1 8.4 Homogeneous
6 Negative 1.5 2+ Positive 3 6.4 Focal
7 Positive 0.5 2+ Positive 2.5 6.1 Focal
8 Positive 2.2 2+ Positive 3.1 8.6 Heterogeneous
9 Positive 4.8 3+ Positive 3.2 10.9 Heterogeneous
10 Positive 0.4 2+ Positive 3.5 7.9 Focal
11 Positive 0.5 2+ Positive 2.5 5.2 Heterogeneous
12 Positive N/A 2+ Positive 6.9 17 Focal
13 Negative 1.7 3+ Negative 1.3 4.1 Homogeneous
14 Positive 4.4 3+ Positive 5.1 9.5 Homogeneous
15 Positive 2.8 3+ Positive 3.8 7.6 Heterogeneous
Abbreviations: ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; ISH, in situ hybridization; N/A, not
available; PR, progesterone receptor; T-DM1+P, trastuzumab emtansine plus pertuzumab.
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